Treatment of chronic bronchitis and COPD in primary care;Tratamiento de la bronquitis cronica y la EPOC en atencion primaria

Archivos de Bronconeumologia

Volumn 35, Issue 4, 1999, Pages 173-178

  Miravitlles, M ^a,c   Murio, C ^a   Guerrero, T ^b   Segu J L ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Div de Pharma Consult Services SA   (Spain)

^c NONE   (Spain)

Author keywords

Chronic bronchitis; COPD; Lung function tests; Primary care; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; MUCOLYTIC AGENT; THEOPHYLLINE; BRONCHODILATING AGENT;

AGED; ARTICLE; CAREGIVER; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DYSPNEA; EMERGENCY WARD; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL PRACTITIONER; HEALTH CARE UTILIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE; SPAIN; SYMPTOM; BRONCHITIS; CHRONIC DISEASE; CLINICAL PRACTICE; DRUG UTILIZATION; GENERAL PRACTICE; LUNG FUNCTION TEST; MIDDLE AGED; STATISTICAL MODEL;

AGED; BRONCHITIS; BRONCHODILATOR AGENTS; CHRONIC DISEASE; DRUG UTILIZATION; FAMILY PRACTICE; FEMALE; GUIDELINE ADHERENCE; HUMANS; LOGISTIC MODELS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RESPIRATORY FUNCTION TESTS; SPAIN;

EID: 0032891513     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-2896(15)30274-x     Document Type: Article

References (23)

1. Brotons B, Pérez JA, Sánchez-Toril F, Soriano S, Hernández J, Belenguer JL. Prevalencia de la enfermedad pulmonar obstructiva crónica y del asma. Estudio transversal. Arch Bronconeumol 1994; 30: 149-152.
2. Comité científico del estudio IBERPOC. Proyecto IBERPOC: un estudio epidemiológico de la EPOC en España. Arch Bronconeumol 1997; 33: 293-299.
3. Sobradillo V, Miravitlles M, Gabriel R, Masa JF, Villasante C, Jiménez CA et al. Prevalence of COPD in seven areas of Spain. Preliminary results of the IBERPOC study. Eur Respir J 1997; 10 (Supl 25): 347.
4. Sánchez Agudo L, Miravitlles M. Manejo de la enfermedad pulmonar obstructiva crónica en la medicina primaria. Arch Bronconeumol 1995; 31: 144-146.
5. Woodhead M, Gialdroni Grassi G, Huchon GJ, Léophonte P, Manresa F, Schaberg T. Use of investigations in lower respiratory tract infection in the community: a European survey. Eur Respir Dis 1996; 9: 1.596-1.600.
6. Montemayor T, Alfajeme Y, Escudero C. Morera J, Sánchez Agudo L. Normativa sobre diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 1996; 32: 285-301.
7. Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL on behalf of the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 1999; 23: 173-179.
8. Roca J, Sanchis A, Agustí-Vidal A, Segarra F, Navajas D, Rodríguez-Roisin R et al. Spirometric reference values from a Mediterranean population. Bull Eur Physiopatol Respir 1986; 22: 271-274.
9. Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152: 77-120.
10. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127: 1.072-1.079.
11. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dysnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
12. Naberán Toña C. Encuesta de la actitud terapéutica y de control de los médicos generales de las ABS de Barcelona respecto a enfermedades obstructivas respiratorias. Aten Primaria (Barc) 1994; 13: 112-115.
13. Sobradillo Peña V, Casan P. Utilidad clínica de la calidad de vida relacionada con la salud. Arch Bronconeumol 1995; 31: 197-198.
14. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P et al. ERS consensus statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society (ERS). Eur Respir J 1995; 8: 1.398-1.420.
15. Kerstjens HAM, Overbeek SE, Schouten JP, Brand PLP, Postma DS and the Dutch CNSLD Study Group. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Eur Respir J 1993; 6: 868-876.
16. Weiner P, Weiner M, Azgad Y, Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest 1995; 108: 1.568-1.571.
17. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffery PK et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1.529-1.534.
18. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-780.
19. Jones PW, Bosh TK in association with an international study group. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1.283-1.289.
20. Miller MA, Fragoso CAV. Review of the clinical efficacy of theophylline in the treatment of chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 147: 40-47.
21. Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med 1998; 92: 256-263.
22. Partridge MR. The implementation of asthma guidelines in general practice. Respir Med 1997; 91: 575-577.
23. Marras TK, Chan CK. Use of guidelines in treating community-acquired pneumonia. Chest 1998; 113: 1.689-1.694.